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ABSTRACT 
Familial microscopic hematuria (FMH) is associated with a genetically heterogeneous group of 
conditions including the collagen-IV nephropathies, the heritable C3/CFHR5 nephropathy and the 
glomerulopathy with fibronectin deposits. The clinical course varies widely, ranging from isolated 
benign familial hematuria to end-stage renal disease (ESRD) later in life. We investigated 24 families 
using Next Generation Sequencing (NGS) for five genes: COL4A3, COL4A4, COL4A5, CFHR5 and 
FN1. In 17 families (71%), we found 15 pathogenic mutations in COL4A3/A4/A5, nine of them novel. 
In five families patients inherited classical AS with hemizygous X-linked COL4A5 mutations. Even 
more patients developed later-onset Alport-related nephropathy having inherited heterozygous 
COL4A3/A4 mutations that cause thin basement membranes. Amongst 62 heterozygous or hemizygous 
patients, eight (13%) reached ESRD, while 25% of patients with heterozygous COL4A3/A4 mutations, 
aged >50-yrs, reached ESRD. In conclusion, COL4A mutations comprise a frequent cause of FMH. 
Heterozygous COL4A3/A4 mutations predispose to renal function impairment, supporting that thin 
basement membrane nephropathy is not always benign. The molecular diagnosis is essential for 
differentiating the X-linked from the autosomal recessive and dominant inheritance. Finally, NGS 
technology is established as the gold standard for the diagnosis of FMH and associated collagen-IV 
glomerulopathies, frequently averting the need for invasive renal biopsies. 
 
Key words: next generation sequencing; COL4A3/COL4A4/COL4A5; familial microscopic hematuria; 
thin basement membrane nephropathy (TBMN); focal segmental glomerulosclerosis (FSGS); end stage 
renal disease (ESRD); Alport Syndrome; later-onset Alport-related nephropathy (LOAN) 
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Introduction 
Familial microscopic hematuria (FMH) is a common presenting feature of glomerular disease and it 
can be associated with later progression to proteinuria and reduced glomerular filtration rate (GFR), 
depending on the specific disease or gene at fault. During the past three decades the correlation 
between molecular genetics and hematuria of glomerular origin has been well described. Six genes 
(COL4A3, COL4A4, COL4A5, CFHR5, MYH9, FN1) have been identified, which when mutated cause 
hereditary forms of microscopic hematuria (MH) (1). In most cases mutations are found in COL4A3, 
COL4A4 or COL4A5 genes that code for the respective alpha chains of the trimeric collagen IV, the 
most important structural component of the glomerular basement membrane (GBM) (2-4). 
Glomerular MH is the earliest presenting sign in males with AS and hemizygous mutations in the X-
linked COL4A5 gene and in males or females with autosomal recessive AS (ARAS) who inherit 
homozygous or compound heterozygous mutations in the COL4A3 or COL4A4 genes. Glomerular MH 
is also the cardinal presenting finding in patients with thin basement membranes, a condition known 
with the descriptive term of thin basement membrane nephropathy (TBMN), which has an estimated 
population prevalence of 0.3-1%. About 40-50% of these patients inherit heterozygous mutations in 
either of the COL4A3/A4 genes, thus actually representing the heterozygous carriers of the ARAS (5-
7). Most patients with AS will progress to ESRD at some point in their early life, usually before the age 
of 30-yrs, while in patients with heterozygous COL4A3/A4 mutations the long term clinical outcome is 
largely unpredictable (8). 
Until recently, TBMN caused by heterozygous COL4A3/A4 mutations and commonly diagnosed in 
early life, was considered as a rather benign condition with excellent prognosis for life, with patients 
demonstrating mostly isolated MH or MH plus added low grade proteinuria of no particular clinical 
significance. However, work on a large Greek-Cypriot cohort and subsequent studies from several 
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other groups around the world, have established that an important percentage of patients with thin 
basement membranes, will develop clinically significant proteinuria later in their lives, usually 
accompanied by hypertension and a variable rate of GFR decline, up to ESRD. They are rarely 
associated with hearing loss (9-12). Work on the same Greek-Cypriot cohort linked COL4A3/A4 
heterozygous mutations with a severe outcome, usually after the 5th decade of life due to focal 
segmental glomerulosclerosis (FSGS) (10, 13). In fact, it is now well clarified that patients with 
heterozygous mutations in the COL4A3/A4 genes can be misdiagnosed with hereditary FSGS (8, 14, 
15). Consequently, many patients with thin basement membranes follow a clinical course reminiscent 
to a milder or later-onset Alport-related nephropathy (LOAN). 
Herewith, we aimed at establishing the frequency of mutations in patients of 24 families from Greece 
presenting with FMH, most of them originating from the island of Crete. The molecular investigation 
was performed with the use of high throughput Next Generation Sequencing (NGS). We found 15 
clearly pathogenic mutations, nine novel, in 17 families. 
 
Materials and Methods 
Patients and families 
We studied 24 Greek families presenting with glomerular FMH that were consecutively referred to our 
centers. They included 237 subjects, of whom 177 were affected patients. DNA was available for 121 
patients. Inclusion criteria required that all families had a minimum of three affected subjects with 
isolated MH or MH plus proteinuria and reduced GFR. Other non-glomerular causes of hematuria were 
excluded. Renal biopsies were available for patients in 14/24 (58.8%) families. In the participating 
clinical units, biopsies are not routinely performed in the presence of isolated MH. Nine out of the 14 
families with available biopsies had at least one biopsy that showed thin membranes on electron 
microscope (EM). Two out of these nine also had signs of AS and four had additional signs of FSGS. 
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For the remaining families, EM study was not available, but a number of them had evidence of FSGS 
on light microscopy. In five families, one or more patients had hearing loss. 
All clinical and biological material was accessible through the University of Cyprus Biobank (16). This 
research project was approved by the Cyprus National Bioethics Committee. 
 
Next generation sequencing (NGS), Sanger DNA sequencing and mutation assessment 
DNA from peripheral blood leucocytes of patients was isolated by a salting out procedure (17) or by 
using the Qiagen Blood Midi Kit (Qiagen, Hilden, Germany). A DNA sample of one patient from each 
family was submitted for NGS analysis. COL4A3, COL4A4 and COL4A5 targeted sequencing was 
performed using a custom Ampliseq panel on the Ion Torrent PGM sequencer (Life Technologies, 
Carlsbad, CA, USA) and results were analyzed as previously described (7). Briefly, by considering all 
processed samples, the mean depth of coverage achieved by targeted NGS was 180x. BAM files were 
submitted to the European Nucleotide Archive (ENA) under the accession number (PRJEB21296). 
Variants were validated by Sanger DNA sequencing that was performed using the ABI BigDye 
Terminator v1.1 Cycle Sequencing Kit and the ABI PRISM 3130xl genetic analyzer (Applied 
Biosystems, Carlsbad, CA, USA). The oligonucleotide sequences were adopted from previous 
publications (10). Sanger DNA re-sequencing or restriction enzymes were used for examination of 
additional family members and healthy controls (Supplementary Table 1). Pathogenicity of each DNA 
variant was assessed based on segregation in the family, resolving to available mutation databases and 
testing a number of healthy controls. Also, in silico assessment of variants was performed by utilizing a 
number of available algorithms including SIFT (18), SNPs3D (19), Grantham scoring (20) and 
Polyphen2 (21) (Table 1), with cutoff values of pathogenicity assessment of missense variants as 
follows: SIFT predicts for every position that aminoacid substitutions are damaging with score less 
than 0.05, otherwise if the score is equal to or greater than 0.05 the particular change is considered 
tolerated. In SNPs3D a positive score indicates a variant classified as non-deleterious, and a negative 
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score indicates a deleterious variant. The Grantham score has a minimum score 0 and the maximum is 
215. Higher scores correspond to higher differences in chemical properties, thus increase the 
probability of a substitution to be damaging. Polyphen 2 scores range from 0 to 1 and higher values 
indicate an increased probability of the amino acid substitution to be damaging. 
 
Results 
Mutations identified and their clinical context 
We identified 15 clearly pathogenic mutations, nine of them novel, in 17 families. Three mutations 
were in the COL4A3, nine mutations in the COL4A4 and five in the COL4A5 gene (Table 1). Two 
mutations are expected to affect splicing, as they involve the invariable splicing consensus sequences 
and one is a single nucleotide deletion in the coding sequence, causing a translation frameshift. 
Fourteen mutations are single amino acid substitutions, 12 of them involving glycine residues in the 
collagenous domain, which are absolutely conserved and indispensable in every third position, in order 
for the triple helix to form normally. Mutation COL4A5-p.C1567R, involves one of the 12 highly 
conserved cysteines in the NC1 domain, which is important for chain recognition during trimer and 
helix formation (22). 
Our NGS gene panel included also CFHR5 and FN1 but no pathogenic mutations were detected in 
either of them. CFHR5 is included because a mutation of exon 2-3 duplication is endemic among 
Cypriots, where our lab is located (23). FN1 is included because when mutated, it is a known rare cause 
of FMH (24). None of the 9 novel missense mutations was present in any of at least 35 normal controls, 
nor were they included in mutation databases, including the HGMD Professional, LOVD and ARUP. 
Certain families are quite extended; nonetheless DNA was not available from all affected individuals. 
Important findings in specific families are described below and in Tables 2 & 3. 
Family CR-5316 
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COL4A4-p.G948Dfs2* (c.2843delG) was found in homozygosity in two young individuals, a girl and a 
boy, who developed severe AS (See Supplementary Figure 1 for all pedigrees). Reportedly, the 
homozygosity in this family could not be attributed to conspicuous parent consanguinity, although they 
all lived in a very remote and isolated village on the island of Crete. This may suggest that the mutation 
had first occurred a long time ago. The boy reached ESRD at age 23-yrs and the girl at age 19-yrs and 
was transplanted towards the end of 2013, at age 22. Their biopsy documented FSGS by light 
microscopy and ultrastructural features of AS by EM. Both children and their mother had hearing loss. 
Of eight heterozygous individuals, three had only MH, four had MH plus proteinuria and one 
developed renal impairment at 53-yrs. Additionally, the patients had variant COL4A4-p.L30F in cis 
configuration with COL4A4-p.G948Dfs2*. Aminoacid residue p.L30 is located on the 7S domain of 
collagen IV. This variant was not found in more than 100 control samples of the general population. It 
is more likely that the causal mutation is p.G948Dfs2*, with p.L30F being a rare variant of unclassified 
significance (VUS). This variant was recently registered independently under rs758174051 [(found in 
4/120780 samples) - ExAc Consortium, Broad Institute, Cambridge, MA, USA)]. In silico analysis 
indicated that it is pathogenic (Table 1). Interestingly, in the same family, variant COL4A4-p.P222L 
was identified in two individuals, mother and daughter. Reportedly, the mother, who also carries the 
pathogenic mutation COL4A4-p.G948Dfs2* in trans, does not have AS. The daughter, who carries 
only COL4A4-p.P222L, did not show MH on one urine test. Additionally, this variant was not found in 
35 normal controls of the general population of Crete, or in more than 100 Greek-Cypriot samples 
tested by NGS. Therefore, excluding the possibility of non-penetrance, variant COL4A4-p.P222L is 
most probably a rare polymorphism, unlikely to be pathogenic. 
Families CR-5408 and CR-5424 
In Cretan families CR-5408 and CR-5424 (Figure 1A and 1B) mutations COL4A4-p.G774R and 
COL4A4-p.G1465D were found in cis configuration in five out of the six patients. One patient in 
family CR-5408 carries only the COL4A4-p.G774R mutation (previously reported by (25), most 
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probably due to a recombination event. COL4A4-p.G1465D was reported previously as a probably 
damaging variant (26). This suggests the primary mutation is COL4A4-p.G774R and that COL4A4-
p.G1465D is either neutral or has a milder effect, although this is a hypothesis to be tested in the future. 
In silico analysis is highly predictive for it being a pathogenic mutation, but for now it remains as VUS 
(Table 1). A biopsy was available from patient IV:2 (MH plus proteinuria at age 19-yrs), showing thin 
basement membranes and focal sites of podocyte effacement, in EM (Figure 2A and 2B). Biopsy was 
available from patient IV:4 of family CR-5424 (Figure 2C) showing FSGS, but unfortunately EM 
analysis was not available. 
Other families studied 
Overall, in this study there was variable clinical information for 62 patients (24M/38F) at ages ranging 
from 16-81 years (Table 2 and Table 3). All mutations identified were invariably associated with MH, 
while 11/42 (26%) of patients with autosomal mutations in COL4A3/A4, had added proteinuria without 
renal impairment and another 9/42 (21%) had progressed to kidney function decline. Six out of the 17 
families studied had at least one biopsy with proven thin basement membranes. Out of 17 carriers of 
heterozygous COL4A3/A4 mutations, older than 50-yrs in this cohort, at least 7 (41%) developed renal 
impairment, while 5 of all 42 (12%) reached ESRD. Importantly, FSGS was reported in patients from 
four of eight families with thin basement membranes and three of five AS families that had biopsies 
performed. Hearing loss was present in patients with X-linked AS, specifically family CR-4245 
(COL4A5-p.G365V), CR-4246 (COL4A5-p.G743V) and CR-4244 (COL4A5-p.G1036R) (Table 3). 
Also hearing loss was evident in a family with ARAS (family CR-5316; mutation COL4A4-
p.G948Dfs2*), as well as in a patient with later-onset Alport related nephropathy (family GR-5499; 
mutation COL4A4-c.489+1G>C) (Table 2).  
Four patients in family GR-5473 presented exclusively with isolated MH. DNA was available from two 
out of four patients that carried the mutation COL4A4-p.G143V. This mutation was previously found in 
a Greek-Cypriot unrelated family, perhaps as a recurrent event, although unknown genetic relationship 
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cannot be excluded (7). Each of mutations COL4A4-p.G748S, COL4A4-p.G774R & p.G1465D was a 
common finding between two seemingly unrelated families (Table 2) and probably represent founder 
effects on the island of Crete. 
Altogether in this cohort (Tables 2 & 3), eight patients (13%, 7M/1F) had progressed to ESRD at ages 
23-65 years. Three of them reached ESRD at an unusually young age: a) A female in family CR-4244 
at age 23-yo (mutation COL4A5-p.G1036R), b) a male in family CR-5363 at age 23-yo (mutation 
COL4A4-p.G748S) and c) a male in family CR-4246 at age 25-yo (mutation COL4A5-p.G743V). In the 
latter case of family CR-4246, rapid progression to ESRD is explained by the very fact that this male 
patient is a misdiagnosed X-linked AS case, supported in further by his reported hearing loss. 
Furthermore, ESRD in case (b) can be attributed to the subject’s extreme obesity, while in case (a) a 
likely explanation could be the skewed inactivation of the X chromosome, as it is a female with a 
heterozygous COL4A5 pathogenic mutation. Her mother and sister with the same mutation present a 
benign phenotype so far. The probability of digenic inheritance is largely excluded as the sample was 
analysed for all COL4 related genes by NGS technology. The role of unknown modifier genes 
predisposing to a more severe outcome is of course another possible explanation. 
Mutation COL4A3-p.G1251S was identified in all affected members of CR-5333, the largest family 
studied in this work with 24 reported patients. Unfortunately, access to only a small number of them 
was possible. Among carriers, three males reached ESRD at ages 55, 61 and 65-yrs. Renal biopsy 
showed thin basement membranes with FSGS in one male and two females. Another male patient 
showed FSGS, while no EM was available. 
 
Phenocopies and incomplete penetrance 
In each one of families GR-5310, CR-4244 and CR-4246 (mutations COL4A4-p.G1154V, COL4A5-
p.G1036R and COL4A5-p.G743V respectively), one phenocopy patient was identified as he presented 
with MH without carrying the respective mutation (27). It is postulated that MH in these patients was 
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due to a different cause. Contrastingly, in family GR-5433 where a splicing defect was found 
(COL4A3-c.765+2T>C), a mutation female carrier appeared completely healthy, a sign of incomplete 
penetrance. Interestingly, her sister died on dialysis (no DNA sample was available), thus showing the 
existence of extreme phenotypes within the same family. Equally important is that a young girl in this 
family, presented in 2013 at age 11-yrs with MH and proteinuria of 500mg/day, accompanied by thin 
basement membranes. She is already on treatment with ACE inhibitors and her kidney function 
remains normal. 
In the same context, in family CR-4245 four patients with MH do not carry the COL4A5-p.G365V 
mutation. We suspect that a second genetic etiology exists for these patients, since married-in 
individuals (DNA sample not available), also had MH (Supplementary Figure 1). 
 
Coding non-pathogenic variants 
We identified 51 polymorphic variants in the coding sequences of all five genes, with some of them 
being novel. Importantly, 39 were non-synonymous, one of which involved a glycine in the 7S domain 
of COL4A3, p.G43R (Table 4). The identification and recording of non-pathogenic variants facilitates 
classification of findings in future investigations, saving time and money (28). 
 
Discussion 
We investigated patients from 24 families with ΜΗ from Greece for mutations in five genes and found 
mutations in 17 (71%). Consider that another elegant publication had found mutations in 80% of 
patients of familial hematuric nephropathies using NGS technology (29). This is the largest genetic 
study performed for FMH in Greece. Heterozygous mutations in COL4A3/A4 genes are known to be 
responsible for FΜΗ, due to thin basement membranes. It is well established that a significant 
percentage of these patients with develop later in life added proteinuria and renal function decline, 
while about 30% will progress to ESRD by the age of 70-yrs, according to previous results (30) (and 
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refs therein). Several authors use the term autosomal dominant AS to characterize patients bearing 
heterozygous COL4A3/A4 mutations, who develop severe disease symptoms that include ESRD and 
rarely hearing loss (26, 31, 32). During the recent International Workshop on AS at Gottingen, 
Germany, September 2015, it was discussed that the term TBMN, which in older literature is associated 
with familial benign hematuria, be negated and substituted by another terminology that would assist in 
consolidating that benign FMH is a misnomer (33). 
Perhaps a better term to describe this condition, reminiscent to, but different from, classical AS, is 
autosomal dominant later-onset Alport-related nephropathy (LOAN); it combines the name of Alport, 
which is a collagen IV nephropathy and the documented later age at onset of serious clinical symptoms 
and ultrastructural or extrarenal findings, if and when they occur (34). Due to the high population 
frequency of LOAN, genetics clinics and laboratories examine more patients who progress to chronic 
renal failure or ESRD because of inheritance of LOAN than patients who inherit classical AS. Similar 
findings concerning the high risk of LOAN patients progressing to renal function decline of variable 
degree, have been reported by several groups, who referred to these patients as having inherited TBMN 
(11, 35-37). 
In a previous publication of our group we reported on 14 families with 54 patients who had solely 
manifested isolated FMH of glomerular origin and we found no mutations in the COL4 genes. 
Presumably these patients have inherited mutations in other, yet unknown, less deleterious genes (7). 
This is another important reason that unknown genes, which when mutated may cause real isolated 
“benign” FMH, should be identified and studied. The molecular diagnosis will be indicative of the 
good prognosis of such patients. Patients from such families may be attracting the attention of 
researchers less frequently or with less interest and escape detailed genetic studies. 
It is important to note that in the current study we focused on deciphering the mutation load of patients 
presenting glomerular FMH, with or without further progression. In five of 24 families there was clear 
segregation of X-linked AS, with mutations in the COL4A5 gene. In the remaining 19 families, 
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mutations in the COL4A3/A4 genes were documented in 12, representing 63%. This is somewhat 
higher than the previously reported 40-50% in biopsy-documented TBMN families (38). This slight 
discrepancy might be explained by the relatively small number of families included here or by the 
structure of the Cretan population which favors founder phenomena, as demonstrated also here, where 
non-related families carried the same mutation. In papers reporting on FMH, mutations in the 
COL4A3/A4 genes were identified in 36%, 38% and 17.5% of 22, 21 and 40 families respectively. 
Also, in another population of Greek-Cypriots we found pathogenic mutations in 27/68 families, 
representing 39.7% (7, 25, 38, 39). 
Although we had limited clinical data for 5/42 patients with identified heterozygous mutations in the 
COL4A3A/A4 genes (Table 2), useful results can be extracted with regards to the disease progression. 
ESRD was observed in 5 patients (12%), at ages of 23, 55, 61, 63 and 65-yrs. Three of them belonged 
to a large Cretan family, CR-5333 (mutation COL4A3-p.G1251S), suggesting that a genetic modifier 
might be co-inherited, predisposing them to adverse outcome at later ages. In addition, by taking into 
account only patients older than 50-yrs, the percentage of reduced GFR is 41% (7/17). This fact 
supports the use of LOAN as an alternative term to describe patients with thin basement membranes 
who can be complicated by proteinuria and decline of kidney function on long follow-up, perhaps with 
the effect of genetic modifiers (40-43). For three such putative modifiers [two in the NPHS2 gene 
(podocin) and one in the NEPH3 gene (filtrin)] co-inherited with a COL4A3 mutation, functional cell 
culture studies were also supportive (42, 43). In the present cohort none of the patients examined 
carried a high risk modifier allele, most probably due to their low population frequency. 
The ages at onset of ESRD in severe LOAN, usually in the 50s-60s, appear to overlap with the ages at 
onset of ESRD in patients with milder X-linked AS, which sometimes may be misdiagnosed as TBMN, 
especially if the pedigree structure is misleading (44-48). This certainly reflects the significant 
phenotypic heterogeneity, which can be partly attributed to the great allelic heterogeneity and partly to 
the likely role of genetic modifiers. Incomplete penetrance also was revealed in this cohort, as some 
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family members remained healthy even though they have inherited the causative mutations. 
Phenocopies are occasional observations that require caution, especially if they happen to be the 
samples chosen for the molecular investigation, thus providing erroneous results of no mutation 
findings. 
 
Conclusions 
1. Patients with FMH should be investigated molecularly for all three COL4 genes. The diagnosis of X-
linked AS in 5 out of 17 families was only documented through genetic analysis, without having 
information to satisfy classical criteria (49). The pedigree structure is not always indicative of the mode 
of inheritance, which is required to provide proper genetic counselling and risk assessment for family 
planning. Consider also, that EM biopsy results at young age cannot differentiate between classical AS 
and TBMN or LOAN. The molecular analysis is the gold standard for the diagnosis and the biopsy 
should be used in more demanding or complicated cases for guiding medical treatment. 
2. It is worth emphasizing that patients with COL4 mutations lacking a molecular diagnosis, can be 
mistakenly diagnosed with primary FSGS upon a positive renal biopsy, thereby undergoing erroneous 
treatments (8, 10, 14, 15). The consensus demands genetic analysis by NGS technology as a first line of 
investigation in most cases of isolated FMH or MH plus added proteinuria before resolving to invasive 
procedures (50). Patients who are positive for heterozygous mutations should be on closer follow-up 
and never left unattended due to the risk for hypertension and later-onset progressive disease. The close 
clinical care and timely institution of therapy upon the appearance of hypertension or proteinuria will 
prolong the kidney function. 
3. Current technologies have revealed hundreds of DNA variants, often of unknown significance. 
Variant analysis includes the extensive screening of online databases (ARUP, LOVD, HGMD, 
Ensembl, dpSNP), while unrecorded findings are systematically evaluated using a number of prediction 
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software for scoring (see Material and Methods), and their frequency is examined in a representative 
sample of the general population. 
4. Equally important is to maintain and curate an in-house database of variants, pathogenic or neutral, 
for easy access during genetic investigations. It is the norm that every population has its own repertoire 
of DNA variants with varying frequencies, especially when serving island populations with strong 
founders like the Cretan, the Cypriot and others. 
5. The term “familial benign hematuria” should be avoided all-together as a misnomer and an 
alternative term, perhaps “Later-Onset Alport-related Nephropathy” could be adopted to describe 
patients with thin basement membranes due to heterozygous COL4 mutations, with Alport-like adverse 
outcomes at older ages. We understand that some authors who find also ultrastructural glomerular 
features pathognomonic for AS, or even extra renal manifestations (although very rare), prefer the use 
of autosomal dominant AS, although this term has not been globally accepted. 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
References 
 
1. Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol 
Dial Transplant 2013: 28: 2946-2960. 
2. Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue 
Res 2010: 339: 167-188. 
3. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol 
Med (Maywood) 2007: 232: 1121-1129. 
4. Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 
2008: 4: 24-37. 
5. Gregory MC. The clinical features of thin basement membrane nephropathy. Seminars in 
nephrology 2005: 25: 140-145. 
6. Savige J, Rana K, Tonna S et al. Thin basement membrane nephropathy. Kidney Int 2003: 64: 
1169-1178. 
7. Papazachariou L, Demosthenous P, Pieri M et al. Frequency of COL4A3/COL4A4 Mutations 
amongst Families Segregating Glomerular Microscopic Hematuria and Evidence for Activation of the 
Unfolded Protein Response. Focal and Segmental Glomerulosclerosis Is a Frequent Development during 
Ageing. PloS one 2014: 9: e115015. 
8. Deltas C, Savva I, Voskarides K et al. Carriers of Autosomal Recessive Alport Syndrome with 
Thin Basement Membrane Nephropathy Presenting as Focal Segmental Glomerulosclerosis in Later Life. 
Nephron 2015: 130: 271-280. 
9. Savige J. Thin basement membrane nephropathy and coincidental renal biopsy lesions. 
Nephrology (Carlton) 2004: 9: 52. 
10. Voskarides K, Damianou L, Neocleous V et al. COL4A3/COL4A4 mutations producing focal 
segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am SOc 
Nephrol 2007: 18: 3004-3016. 
11. Marcocci E, Uliana V, Bruttini M et al. Autosomal dominant Alport syndrome: molecular analysis 
of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 2009: 24: 1464-1471. 
12. Nabais Sa MJ, Storey H, Flinter F et al. Collagen type IV-related nephropathies in Portugal: 
pathogenic COL4A3 and COL4A4 mutations and clinical characterization of 25 families. Clin Genet 
2015: 88: 456-461. 
13. Pierides A, Voskarides K, Athanasiou Y et al. Clinico-pathological correlations in 127 patients in 
11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/ COL4A4 genes 
associated with familial haematuria and significant late progression to proteinuria and chronic kidney 
disease from focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009: 24: 2721-2729. 
14. Gast C, Pengelly RJ, Lyon M et al. Collagen (COL4A) mutations are the most frequent mutations 
underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2015: 31: 961-970. 
15. Malone AF, Phelan PJ, Hall G et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken 
for familial focal segmental glomerulosclerosis. Kidney Int 2014: 86: 1253-1259. 
16. University of Cyprus Biobank (CY-Biobank) N, Cyprus; Multiple Access, Last: December 2014. 
[BIORESOURCE]. 
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from 
human nucleated cells. Nucleic Acids Res 1988: 16: 1215. 
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on 
protein function using the SIFT algorithm. Nat Protoc 2009: 4: 1073-1081. 
19. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. 
BMC Bioinformatics 2006: 7: 166. 
20. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974: 185: 
862-864. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
21. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense 
mutations. Nature Methods 2010: 7: 248-249. 
22. Knebelmann B, Breillat C, Forestier L et al. Spectrum of mutations in the COL4A5 collagen gene 
in X-linked Alport syndrome. Am J Hum Genet 1996: 59: 1221-1232. 
23. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 
mutations: clinical characteristics of 91 patients in 16 pedigrees. Clinical J Am Soc Nephrol 2011: 6: 
1436-1446. 
24. Castelletti F, Donadelli R, Banterla F et al. Mutations in FN1 cause glomerulopathy with 
fibronectin deposits. Proc National Acad Sciences (USA) 2008: 105: 2538-2543. 
25. Slajpah M, Gorinsek B, Berginc G et al. Sixteen novel mutations identified in COL4A3, 
COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign familial 
hematuria. Kidney int 2007: 71: 1287-1295. 
26. Fallerini C, Dosa L, Tita R et al. Unbiased next generation sequencing analysis confirms the 
existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2014: 86: 
252-257. 
27. Hertz JM. Alport syndrome. Molecular genetic aspects. Danish medical bulletin 2009: 56: 105-
152. 
28. Savige J, Ars E, Cotton RG et al. DNA variant databases improve test accuracy and phenotype 
prediction in Alport syndrome. Pediatr Nephrol 2014: 29: 971-977. 
29. Moriniere V, Dahan K, Hilbert P et al. Improving mutation screening in familial hematuric 
nephropathies through next generation sequencing. J Am Soc Nephrol 2014: 25: 2740-2751. 
30. Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol 
Dial Transplant 2013: 28: 2946-2960. 
31. Rosado C, Bueno E, Felipe C et al. Study of the True Clinical Progression of Autosomal 
Dominant Alport Syndrome in a European Population. Kidney Blood Press Res 2015: 40: 435-442. 
32. Rosado C, Bueno E, Fraile P et al. A new mutation in the COL4A3 gene responsible for 
autosomal dominant Alport syndrome, which only generates hearing loss in some carriers. Eur J Med 
Genet 2015: 58: 35-38. 
33. Gross O, Kashtan CE, Rheault MN et al. Advances and unmet needs in genetic, basic and clinical 
science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol 
Dial Transplant 2016: 
34. Kovacs G, Kalmar T, Endreffy E et al. Efficient Targeted Next Generation Sequencing-Based 
Workflow for Differential Diagnosis of Alport-Related Disorders. PloS one 2016: 11: e0149241. 
35. Temme J, Peters F, Lange K et al. Incidence of renal failure and nephroprotection by RAAS 
inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney 
Int 2012: 81: 779-783. 
36. Tonna S, Wang YY, MacGregor D et al. The risks of thin basement membrane nephropathy. 
Seminars in nephrology 2005: 25: 171-175. 
37. Weber S, Strasser K, Rath S et al. Identification of 47 novel mutations in patients with Alport 
syndrome and thin basement membrane nephropathy. Pediatr Nephrol 2016: 31: 941-955. 
38. Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with 
haplotypes at the loci for Alport syndrome. Kidney Int 2001: 59: 1670-1676. 
39. Rana K, Wang YY, Powell H et al. Persistent familial hematuria in children and the locus for thin 
basement membrane nephropathy. Pediatr Nephrol 2005: 20: 1729-1737. 
40. Tonna S, Wang YY, Wilson D et al. The R229Q mutation in NPHS2 may predispose to 
proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol 2008: 23: 2201-2207. 
41. Voskarides K, Arsali M, Athanasiou Y et al. Evidence that NPHS2-R229Q predisposes to 
proteinuria and renal failure in familial hematuria. Pediatr Nephrol 2012: 27: 675-679. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
42. Stefanou C, Pieri M, Savva I et al. Co-Inheritance of Functional Podocin Variants with 
Heterozygous Collagen IV Mutations Predisposes to Renal Failure. Nephron 2015: 130: 200-212. 
43. Voskarides K, Stefanou C, Pieri M et al. A functional variant in NEPH3 gene confers high risk of 
renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in 
the general population. PloS one 2017: 12: e0174274. 
44. Pierides A, Voskarides K, Kkolou M et al. X-linked, COL4A5 hypomorphic Alport mutations 
such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria 
and late onset kidney failure. Hippokratia 2013: 17: 7. 
45. Demosthenous P, Voskarides K, Stylianou K et al. X-linked Alport syndrome in Hellenic 
families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5. 
Clin Genet 2012: 81: 240-248. 
46. Barker DF, Pruchno CJ, Jiang X et al. A mutation causing Alport syndrome with tardive hearing 
loss is common in the western United States. Am J Hum Genet 1996: 58: 1157-1165. 
47. Martin P, Heiskari N, Zhou J et al. High mutation detection rate in the COL4A5 collagen gene in 
suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998: 9: 2291-
2301. 
48. Wilson JC, Yoon HS, Walker RJ et al. A novel Cys1638Tyr NC1 domain substitution in 
alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye 
abnormalities. Nephrol Dial Transplant 2007: 22: 1338-1346. 
49. Hanson H, Storey H, Pagan J et al. The value of clinical criteria in identifying patients with X-
linked Alport syndrome. Clinical J Am Soc Nephrol 2011: 6: 198-203. 
50. Miner JH, Baigent C, Flinter F et al. The 2014International Workshop on Alport Syndrome. 
Kidney Int 2014: 86: 679-684. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Figure legends 
Figures 1A & 1B: Pedigrees of families CR-5408 and CR-5424, with patients that carry two mutations, 
COL4A4-p.G774R and COL4A4-p.G1465D in cis. Judging from the fact that patient IV-2 in CR-5408 
carries only mutation COL4A4-p.G774R, this is definitely pathogenic. Patients in these families had 
features of progressive disease, with biopsies featuring podocyte effacement and focal segmental 
glomerulosclerosis. 
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Figure 2A & 2B: Electron microscope of biopsy from patient IV-2, family CR-5408. There is thinning of 
the glomerular basement membrane, average thickness of 190 nm, with regions of podocyte foot process 
effacement. 
 
Figure 2C: Light microscope of biopsy from patient IV-4, family CR-5424. Thin basement membranes, 
glomerular tuft synechia close to the uric pole and relative glomerulomegaly for patient’s age. PASx400 
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Τable 1: Information on the 15 pathogenic mutations identified here, plus the two variants of unclassified significance (VUS: COL4A4-
p.L30F and COL4A4-p.G1465D). Underlined are the nine novel mutations identified here. NA: Not Available  
 
Gene Coding Protein dbSNP entry MAF SIFT SNPs3D Grantham Polyphen-2 Reference 
COL4A3 c.765+2T>C  rs869025326 NA NA NA NA NA 
(Kovacs, Kalmar et 
al. 2016) 
 
COL4A3 c.1006G>T p.G336C NA NA 0.00 -2.74 159 1.000 (Fallerini, Dosa et al. 2014) 
COL4A3 c.3751C>A p.G1251S NA NA 0.00 -2.70 56 1.000 Novel – this study 
COL4A4 c.88T>C p.L30F rs758174051 A=0.00003/4 (ExAC) 0.06 NA 22 0.976 NA 
COL4A4 c.428G>T p.G143V NA NA 0.00 -3.71 109 1.000 
(Papazachariou, 
Demosthenous et al. 
2014) 
COL4A4 c.489+1G>C  NA NA NA NA NA NA Novel – this study 
COL4A4 c.2242G>A p.G748S rs762139460  
T=0.00004/5 
(ExAC) 0.00 -2.29 56 0.954 Novel – this study 
COL4A4 c.2320G>C 
 
p.G774R 
 
rs569681869 G=0.00009/11 (ExAC) 0.00 -4.07 125 1.000 
(Slajpah, Gorinsek 
et al. 2007) 
COL4A4 c.2843delG p.G948Dfs2* NA NA NA NA NA NA Novel – this study 
COL4A4 c.3044G>A p.G1015E rs764323652 T=0.00005/6 (ExAC) 0.01 -3.23 98 1.000 Novel – this study 
COL4A4 c.3461G>T p.G1154V NA NA 0.00 -4.68 109 1.000 Novel – this study 
COL4A4 c.4393G>A p.G1465D rs533297350 T=0.00009/11 (ExAC) 0.06 -2.61 94 0.999 
(Fallerini, Dosa et 
al. 2014) 
COL4A5 c.1094G>T p.G365V NA NA 0.00 -3.07 110 1.000 Novel – this study 
COL4A5 c.2228G>T p.G743V NA NA 0.00 -4.37 109 1.000 Novel – this study 
COL4A5 c.3106G>A 
 
p.G1036R 
 
NA NA 0.00 -4.39 125 1.000 (Hertz 2009) 
COL4A5 c.4060G>A 
 
p.G1354S 
 
NA NA 0.03 -3.38 56 1.000 Novel – this study 
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COL4A5 c.4699T>C p.C1567R rs104886288 NA 0.00 -3.13 180 1.000 
(Knebelmann, 
Breillat et al. 1996) 
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Table 2: Clinical and pathologic data for the families with a heterozygous pathogenic mutation in the COL4A3 or COL4A4 gene. All families had been referred for 
genetic investigation because of the presence of familial microscopic hematuria. Some families had many more subjects than DNA available for these studies. 
 
 
Family 
Mutation carriers 
(molecularly 
confirmed) Biopsy Results Mutation 
MH 
Only (age) 
MH+ 
Proteinuria, 
Normal 
GFR (age) 
Impaired 
renal 
function 
OR 
ESRD (age) 
Not 
clinically 
tested (age) 
ESRD 
(age) 
Total ♂ ♀ 
CR-4214 1 0 1 
mesangio-hyperplastic GN, focal 
sclerosis, IgM+, C3+, weak 
COL4A5 in IHC (1♀) 
COL4A4-p.G748S 0 1♀ (56) 0 0 0 
GR-5310 1 0 1 TBMN (1♀) COL4A4-p.G1154V 0 1♀ (78) 0 0 0 
CR-5316* 8 5 3 *FSGS (no EM) (1♀) 
COL4A4-c.2843delG 
(p.G948Dfs2*) 
/COL4A4-p.L30F 
3♂ (22, 29, 39) 
2♂ (50, 81) 
2♀ (42, 56) 
1♀ (53) 0 0 
CR-5319 4 1 3 ND COL4A3-p.G336C 
1♂ (16) 
1♀ (52) 
0 0 2♀ (21, 88) 0 
CR-5333 9 4 5 
TBMN-FSGS (1♂, 2♀,) 
FSGS (no EM) (1♂) 
COL4A3-p.G1251S 1♀ (22) 2♀ (46, 57) 
3♂ 
(64, 70, 76) 
1♂ (?) 
2♀ (31, ?) 
3♂ (65, 
61, 55) 
CR-5363 4 2 2 
TBMN-FSGS (1♂) 
FSGS, IgM+, C3+ (no EM) (1♂) 
COL4A4-p.G748S 1♀ (38) 0 
2♂ (34, 72) 
1♀ (46) 
0 1♂ (23)
CR-5408 4 3 1 TBMN (1♂) COL4A4-p.G774R /  COL4A4-p.G1465D 
2♂ (47, 69) 
1♀ (45) 
1♂ (19)** 0 0 0 
GR-5416 1 1 0 ND COL4A4-p.G1015E 0 0 1♂ (55) 0 0 
CR-5424 2 1 1 TBMN-Alport (1♀) COL4A4-p.G774R /  COL4A4-p.G1465D 
1♂ (62) 
1♀ (20) 
0 0 0 0 
GR-5433 3 0 3 TBMN-FSGS  (2♀) COL4A3-c.765+2 T>C 1♀ (67 asympt.) 2♀ (12, 41) 0 0 0 
GR-5473 2 0 2 ND COL4A4-p.G143V 2♀ (7, ?) 0 0 0 0 
GR-5499 3 2 1 ND COL4A4-c.489+1 G>C 
1♂ (42) 
1♀ (39) 
0 1♂ (75) 0 1♂ (63)
SUM 
(%) 
42 
100% 
19 
45% 
23 
55% 
13 12 
8♂/9♀ 
40,5% 
3♂/8♀ 
26% 
7♂/2♀ 
21% 
1♂/2♀ 
7% 
5♂ 
12% 
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*Two patients of this family have Alport Syndrome due to homozygosity (one biopsy proven) and are not included in this table.  
**This patient is carrier only for the COL4A4-p.G774R mutation. 
? Not known 
 
ESRD, End-stage renal disease; EM, Electron Microscope; FSGS, Focal segmental glomerulosclerosis; MH, Microscopic hematuria; ND, Not done or not 
determined with certainty; TBMN, Thin basement membrane nephropathy; CR, Cretan origin; GR, Greek origin (not Cretan) 
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Table 3: Clinical and pathologic data for the families with a pathogenic mutation in the X-linked COL4A5 gene. All families had been referred for genetic 
investigation because of the presence of familial microscopic hematuria and not Alport syndrome. Some families had many more subjects than DNA available for 
these studies. 
 
 
? Not known 
 
CRF, Chronic renal failure; ESRD, End-stage renal disease; EM, Electron Microscope; FSGS, Focal segmental glomerulosclerosis; MH, Microscopic hematuria; 
ND, Not done or not determined with certainty; TBMN, Thin basement membrane nephropathy; CR, Cretan origin; GR, Greek origin (not Cretan); MePGN, 
membrano-proliferative glomerulonephritis 
 
Family 
Mutation carriers 
(molecularly confirmed) 
 
Biopsy Results Mutation MH Only (age) 
MH+ 
Proteinuria, 
Normal GFR 
(age) 
Impaired renal 
function OR 
ESRD (age) 
ESRD (age) 
Total 
 ♂ ♀ 
GR-4242 4 1 3 Immuno-deposits  (1♀) COL4A5-p.G1354S 
1♂ (14) 
2♀ (39, 47) 
0 1♀ (59) 0 
GR-4243 3 1 2 ND COL4A5-p.C1567R 
1♂ (8) 
1♀ (10) 
1♀ (37) 0 0 
CR-4244 3 0 3 
FSGS (no EM) (1♀) 
MePGN-FSGS (1♀) 
COL4A5-p.G1036R 0 2♀ (34, ?) 1♀ (32) 1♀ (23) 
CR-4245 5 1 4 FSGS (no EM) (2♂) COL4A5-p.G365V 4♀ (17, 18, 19, 21) 0 1♂ (49) 1♂ (28) 
CR-4246 5 2 3 FSGS (no EM) (1♂) COL4A5-p.G743V 2♀ (14, 48) 
1♂ (14) 
1♀ (14) 
1♂ (46) 1♂ (25) 
SUM 
(%) 
20 
100% 
5 
25% 
15 
75% 
6 5 
11 
55% 
1♂/4♀ 
25% 
2♂/2♀ 
20% 
2♂/1♀ 
15% 
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Table 4: Non-pathogenic coding variants found by NGS in COL4A3, COL4A4, COL4A5, CFHR5 and 
FN1 genes. Two variants, CFHR5-p.Y565C and FN1-p.T700=, have not been found in any of the 
databases looked for (Ensembl, ClinVar, HGMD, LoVD) and remain as variants of unclassified 
significance. 
 Gene Change in coding sequence 
Change in protein 
sequence SNP code MAF 
1 COL4A3 c.127G>C p.G43R rs13424243 C-23% 
2 COL4A3 c.172G>A p.G58S rs184730597 A-0.02%  
3 COL4A3 c.222G>T  p.P74= rs187950806 T<0.01% 
4 COL4A3 c.373T>C p.C125R This study N/A 
5 COL4A3 c.422T>C p.L141P rs10178458 C-20% 
6 COL4A3 c.485A>G p.E162G rs6436669 A-20% 
7 COL4A3 c.976G>T p.D326Y rs55703767 T-12% 
8 COL4A3 c.1195C>T p.L399= rs10205042 C-23% 
9 COL4A3 c.1223G>A p.R408H rs34505188 A-10% 
10 COL4A3 c.1352A>G p.H451R rs11677877 G-11% 
11 COL4A3 c.1452G>A  p.G484= rs34019152 A-11% 
12 COL4A3 c.1721C>T p.P574L rs28381984 T-40% 
13 COL4A3 c.3258G>A p.G1086= rs147085074 A-0.3% 
14 COL4A3 c.3807C>A p.D1269E rs57611801 A-4% 
15 COL4A3 c.4494C>G p.T1498= rs200454769 G-0.06% 
16 COL4A4 c.665C>T  p.P222L rs773533313  T-0.02% 
17 COL4A4 c.1413A>G p.K471= This study N/A 
18 COL4A4 c.1444C>T p.P482S rs2229814 C-45% 
19 COL4A4 c.1634G>C p.G545A rs1800516 C-0.02% 
20 COL4A4 c.3011C>T p.P1004L rs1800517 C-45% 
21 COL4A4 c.3594G>A p.G1198= rs10203363 A-50% 
22 COL4A4 c.3684G>A p.K1228= rs2229812 A-50% 
23 COL4A4 c.3979G>A p.V1327M rs2229813 A-49% 
24 COL4A4 c.4080G>A p.P1360= rs2228556 A=49% 
25 COL4A4 c.4207T>C p.S1403P rs3752895 T-47% 
26 COL4A4 c.4548A>G p.V1516= rs2228555 A-36% 
27 COL4A4 c.4932C>T  p.F1644= rs2228557 T-46% 
28 COL4A5 c.2896A>G p.K966E This study N/A  
29 COL4A5 c.3513A>G  p.Q1171= rs2273051 G-17% 
30 COL4A5 c.3519T>G p.G1173= rs61735627 G-0.03% 
31 CFHR5 c.136C>T p.P46S rs12097550 T-1% 
32 CFHR5 c.432A>T p.K144N rs181511327 T<1% 
33 CFHR5 c.576T>G p.F192L rs151134004 G<1% 
34 CFHR5 c.1067G>A p.R356H rs35662416 A-2% 
35 CFHR5 c.1694A>G p.Y565C This study N/A 
36 FN1 c.44A>T p.Q15L rs1250259 T-14% 
37 FN1 c.378C>T p.I126I rs2289202 T-14% 
38 FN1 c.1070G>A p.G357E rs140926439 A<1% 
39 FN1 c.1110G>A p.T369T rs149123808 A<1% 
40 FN1 c.2091C>T p.F697F rs149878788 T<1% 
41 FN1 c.2100C>T p.T700T This study N/A 
42 FN1 c.2442T>A p.P814P rs7596677 A-47% 
43 FN1 c.2449A>C p.T817P rs2577301 A<1% 
44 FN1 c.2489G>A p.R830H rs775576039 A<1% 
45 FN1 c.3111A>C p.G1037G rs7589580 C-29% 
46 FN1 c.3156A>C p.P1052P rs1053238 C-29% 
47 FN1 c.4725A>G p.E1484E rs13652 G-13% 
48 FN1 c.5691A>T p.G1897G rs1132741 T-32% 
49 FN1 c.6634A>G p.I2212V rs17449032 G-16% 
50 FN1 c.6781G>A p.V2261I rs1250209 G<1% 
51 FN1 c.7161T>C p.Y2387Y rs11651 G-28% 
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